The recent price action has definitely been strange, but after all the news we have received recently (very strong sales growth and very positive reimbursement news to name a couple) and at such a low valuation, it's pretty easy to sit comfortably here and wait for the market to do its thing. The sales are only moving higher, and fast, and it's quite clear that they will soon be very profitable. Plenty of cash, no debt. A long runway for future growth as well with an abundance of additional expansion opportunities. A clear market leading device with a very strong and sturdy moat. Experienced long-term management team. Ticks plenty of boxes imo. Hopefully the price will explode into dollars soon enough, but this is certainly not a stressful stock to hold through the swings (perhaps frustrating though).
- Forums
- ASX - By Stock
- EYE
- CMS Proposes Major Increase in Reimbursement for Canaloplasty
CMS Proposes Major Increase in Reimbursement for Canaloplasty, page-190
-
-
- There are more pages in this discussion • 318 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add EYE (ASX) to my watchlist
(20min delay)
|
|||||
Last
16.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $36.64M |
Open | High | Low | Value | Volume |
16.0¢ | 16.0¢ | 15.5¢ | $39.30K | 249.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 80000 | 15.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
16.0¢ | 114260 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 80000 | 0.155 |
5 | 137000 | 0.150 |
8 | 558724 | 0.145 |
10 | 407230 | 0.140 |
2 | 14500 | 0.135 |
Price($) | Vol. | No. |
---|---|---|
0.160 | 114260 | 3 |
0.165 | 119997 | 2 |
0.170 | 200000 | 3 |
0.175 | 100000 | 1 |
0.180 | 100000 | 1 |
Last trade - 13.44pm 13/11/2024 (20 minute delay) ? |
Featured News
EYE (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online